NZ507901A - Isolated myelin basic protein (MBP) for treating mutliple sclerosis - Google Patents

Isolated myelin basic protein (MBP) for treating mutliple sclerosis

Info

Publication number
NZ507901A
NZ507901A NZ507901A NZ50790199A NZ507901A NZ 507901 A NZ507901 A NZ 507901A NZ 507901 A NZ507901 A NZ 507901A NZ 50790199 A NZ50790199 A NZ 50790199A NZ 507901 A NZ507901 A NZ 507901A
Authority
NZ
New Zealand
Prior art keywords
basic protein
myelin basic
thr
phe
ile
Prior art date
Application number
NZ507901A
Inventor
Subhashini Arimilli
Shrikant Deshpande
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of NZ507901A publication Critical patent/NZ507901A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A myelin basic protein (MBP) peptide has an amino acid sequence of Phe-X-Lys-Asn-Ile-Val-X-X-X-Thr-X-X, wherein X is any amino acid. Preferably the sequence is Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro-Pro. Also described are antibodies and a composition comprising an MHC Class II complex, capable of binding a T cell receptor, and a myelin basic protein peptide of the sequence Phe-X-Lys-R1-Ile-Val-X-X-X-Thr-X-X, wherein X is any amino acid and R1 is Asn or Gln. The complex consists of An MHC Class II polypeptide comprising an extracellular domain of an MHC Class II molecule sufficient to form an antigen binding pocket wherein the Class II component is encoded by an allele associated with an autoimmune disease directed to myelin basic protein and is soluble under physiology conditions in the absence of detergent or lipid. The composition and the peptide are useful in inhibiting a T-cell mediated immune response, preferably wherein the T-cell mediated immune response causes a pathology to the a neurological system i.e. multiple sclerosis.
NZ507901A 1998-05-05 1999-05-05 Isolated myelin basic protein (MBP) for treating mutliple sclerosis NZ507901A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7310998A 1998-05-05 1998-05-05
PCT/US1999/009930 WO1999057241A2 (en) 1998-05-05 1999-05-05 Myelin basic protein peptides and uses thereof

Publications (1)

Publication Number Publication Date
NZ507901A true NZ507901A (en) 2003-06-30

Family

ID=22111789

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ507901A NZ507901A (en) 1998-05-05 1999-05-05 Isolated myelin basic protein (MBP) for treating mutliple sclerosis

Country Status (10)

Country Link
EP (1) EP1080185A4 (en)
JP (1) JP2002513558A (en)
CN (1) CN1308671A (en)
AU (1) AU3789099A (en)
CA (1) CA2330826A1 (en)
HK (1) HK1039636A1 (en)
NO (1) NO20005547L (en)
NZ (1) NZ507901A (en)
WO (1) WO1999057241A2 (en)
ZA (1) ZA200006268B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
AU2002254753C1 (en) * 2001-05-01 2008-09-18 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
ITFI20010114A1 (en) 2001-06-22 2002-12-22 Univ Firenze GLYCOPEPTIDES, THEIR PREPARATION AND THEIR USE IN THE DIAGNOSIS OR THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
US20110142866A1 (en) * 2007-11-20 2011-06-16 Eldrug S.A. Peptide analogues and conjugates thereof
US20180064792A1 (en) * 2015-03-30 2018-03-08 Osaka University Immunizing peptide, method for producing immunizing peptide, pharmaceutical composition for immune disease containing same, and method for treating immune disease
CN114258317A (en) * 2019-06-18 2022-03-29 斯克里普斯研究学院 Methods and compositions for treating inflammatory disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
AU4278296A (en) * 1994-10-25 1996-05-15 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
EP0833930A2 (en) * 1995-06-07 1998-04-08 ZymoGenetics, Inc. Fused soluble mhc heterodimer:peptide complexes and their uses

Also Published As

Publication number Publication date
JP2002513558A (en) 2002-05-14
CN1308671A (en) 2001-08-15
WO1999057241A9 (en) 2000-02-17
NO20005547L (en) 2001-01-02
ZA200006268B (en) 2001-08-22
NO20005547D0 (en) 2000-11-03
EP1080185A4 (en) 2005-01-26
HK1039636A1 (en) 2002-05-03
EP1080185A2 (en) 2001-03-07
CA2330826A1 (en) 1999-11-11
WO1999057241A2 (en) 1999-11-11
AU3789099A (en) 1999-11-23
WO1999057241A3 (en) 2000-01-13

Similar Documents

Publication Publication Date Title
Salter et al. A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2
EP0997477A3 (en) MHC complexes and uses thereof
Beisiegel et al. The LDL–receptor–related protein, LRP, is an apolipoprotein E-binding protein
Lobb et al. Immunoglobulin light chain classes in a teleost fish.
Sivori et al. p46, a novel natural killer cell–specific surface molecule that mediates cell activation
Harding et al. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation
Accolla et al. Distinct forms of both alpha and beta subunits are present in the human Ia molecular pool.
Lanier Natural killer cell receptors and MHC class I interactions
EP1526141A3 (en) MHC complexes and uses thereof
ATE415173T1 (en) PAN DR BINDING PROTEINS TO INCREASE THE IMMUNE RESPONSE
CA2290485A1 (en) Method for the production of non-immunogenic proteins
Karagiannis et al. Endocytosis and recycling of the complex between CD23 and HLA‐DR in human B cells
EP0340793A3 (en) Endowing cells with antibody specificity
IL142905A0 (en) Functional antagonists of hedgehog activity
EP1273304A3 (en) Use of interleukin-15
CA2248667A1 (en) Hla-a2.1 binding peptides and their uses
CA2296737A1 (en) Ligand for herpes simplex virus entry mediator and methods of use
EP0820469A4 (en) Identification, purification and uses of leczymes and carbohydrate ligands
Brouns et al. Assembly and intracellular transport of the human B cell antigen receptor complex
Johnson et al. A novel arginine vasopressin-binding peptide that blocks arginine vasopressin modulation of immune function.
NZ507901A (en) Isolated myelin basic protein (MBP) for treating mutliple sclerosis
GR3030152T3 (en) A human t-cell receptor of the g-protein coupled receptor family
Stöckel et al. Refolding of human class II major histocompatibility complex molecules isolated from Escherichia coli. Assembly of peptide-free heterodimers and increased refolding-yield in the presence of antigenic peptide.
Strominger et al. Isolation of histocompatibility antigens and of several B cell specific proteins from cultured human lymphocytes
Ishihara et al. Multiple B29 containing complexes on murine B lymphocytes. Common and stage-restricted Ig-associated polypeptide chains.

Legal Events

Date Code Title Description
PSEA Patent sealed